NCT03984448 2026-04-13
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
National Cancer Institute (NCI)
Children's Cancer Group, China
University of Birmingham
Children's Oncology Group
Beijing Pearl Biotechnology Limited Liability Company